País: Austrália
Língua: inglês
Origem: APVMA (Australian Pesticides and Veterinary Medicines Authority)
AMOXICILLIN TRIHYDRATE; POTASSIUM CLAVULANATE
AVET HEALTH LIMITED
ORAL TABLET
AMOXICILLIN TRIHYDRATE ACTIVE Active 400.0 mg; POTASSIUM CLAVULANATE ANTIBIOTIC Active 100.0 mg
100 Tablets
VM - Veterinary Medicine
ANTIBIOTIC & RELATED
Poison schedule: 4; Withholding period: MEAT: CALVES - DO NOT USE less than 4 da ys before slaughter for human consumptio n. Any variation by the prescribing vet erinarian to the approved dose, frequenc y, duration, route, disease or target sp ecies may result in the need to extend t he approved withholding period. EXPOR T SLAUGHTER INTERVAL (ESI): An ESI has n ot been established for this product. N ote - observing the meat withholding per iod may not be sufficient to mitigate po tential risks to export trade. Trade adv ice should be sought from Avet Health LT D on 1800 28 38 28 before using this pro duct.; Host/pest details: CALF: [ANTIBIOTICS - ORAL, PARENTERAL, BACTERIAL INFECTION]; DOG: [ANTIBIOTICS - ORAL, PARENTERAL, BACTERIAL INFECTION]
Registered
2023-09-13
Product Name: APVMA Approval No: AVET Amoxyclav 500 mg Tablets 93475/139283 Label Name: AVET Amoxyclav 500 mg Tablets Signal Headings: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Constituent Statements: Each tablet contains 400 mg AMOXYCILLIN as AMOXYCILLIN TRIHYDRATE and 100 mg CLAVULANIC ACID as DILUTED POTASSIUM CLAVULANATE. Claims: For use by or under direction of a veterinarian. For the treatment of bacterial infections sensitive to clavulanic acid and amoxicyllin in calves and dogs. AVET Amoxyclav 500 mg Tablets have a notably broad spectrum of bactericidal activity against bacteria commonly found in calves and dogs and are indicated for the oral treatment of bacterial infections caused by susceptible organisms. These include enteritis, respiratory tract infections and skin infections in dogs. PRODUCT SUMMARY • Dual action of clavulanic acid and amoxycillin. • Extended spectrum of activity - clavulanate extends the spectrum of amoxycillin by making it active against resistant (B-lactamase producing) strains of Staphylococcus spp., E. coli and Salmonella spp., as well as adding Klebsiella spp. to the list of susceptible organisms. • Rapid bactericidal action - increases the likelihood of a rapid clinical cure. • Excellent absorption and penetration. • Easy to administer. • Convenient twice daily dosage. • Absorption not significantly affected by food. MODE OF ACTION Resistance to many antibiotics is caused by B-lactamase enzymes which destroy the antibiotic before it can act on the bacteria. The clavulanate in AVET Amoxyclav counteracts this defence mechanism by inactivating the B-lactamases, thus rendering the organisms sensitive to amoxycillin's rapid bactericidal effect at concentrations readily attainable in the body. In vitro AVET Amoxyclav is active against a wide range of clinically important bacteria, including: Gram - positive Staphylococcus spp (including B-lactamase producing strains); Corynebacterium spp.; Streptococcus spp. RLP APPROVED Gram - Leia o documento completo